阿奇霉素诱发心血管不良反应事件的临床研究进展  

Clinical research progress of azithromycin-induced cardiac vascular events

作　　者：雷虹[1] 杨莹[1] 郭琪[1] LEI Hong, YANG Ying, GUO Qi(Division of Traditional Medicine, Institute for Drug andlnstrumental Control of Beo＇ing Military Command, Beijing 100071, China)

机构地区：[1]北京军区联勤部药品仪器检验所中药室,北京100071

出　　处：《临床药物治疗杂志》2018年第2期31-33,38,共4页Clinical Medication Journal

摘　　要：尽管在诱发心血管不良反应事件上,阿奇霉素被认为是相对最安全的大环内酯类抗生素。但随着其诱发严重心律失常甚至心源性死亡的报导越来越多,这一说法得到了质疑。因此,本文选取近年来发表的关于阿奇霉素和不良心血管反应事件,尤其是心源性死亡风险的临床研究进行分析归纳,全面考察阿奇霉素的用药安全性,以期为临床合理使用阿奇霉素提供理论依据。Azithromycin was considered as the safest antibiotic among macrolides since it seldom induced cardiovascular side effects. However, we highly doubted this statement after more and more papers reported that azithromycin could induce serious ventricular arrhythmia and even sudden cardiac death. Therefore, we searched several databases for cardiac events caused by azithromycin, and paid special attention to azithromycin-induced cardiac death so as to help clinicians prescribing azithromycin more rationally.

关 键 词：阿奇霉素 心律失常 心源性死亡 Q-T间期延长 

分 类 号：R978.15[医药卫生—药品]